Volume 6.08 | Mar 6

Mammary Cell News 6.08 March 6, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Holding On and Hiding Out: How Cancer Cells Spread to the Brain and Thrive
Scientists have looked into why most circulating tumor cells die upon reaching the brain and why, in exceptional cases, other cells don’t. They have identified genes and proteins that control the survival of metastatic breast and lung cancer cells in the brain. [Press release from Memorial Sloan Kettering Cancer Center discussing online prepublication in Cell] Press Release | Abstract | Graphical Abstract
See Who's Published: Leading Breast Cancer Researchers Use MammoCult™
PUBLICATIONS (Ranked by impact factor of the journal)

DLC1-Dependent Parathyroid Hormone-Like Hormone Inhibition Suppresses Breast Cancer Bone Metastasis
Scientists report that deleted in liver cancer 1 (DLC1) is an important regulator of TGF-ß responses and osteolytic metastasis of breast cancer cells. [J Clin Invest] Full Article

Nuclear Receptor NR4A1 Promotes Breast Cancer Invasion and Metastasis by Activating TGF-ß Signalling
Inflammatory cytokines potently induce NR4A1 expression, and potentiate TGF-ß-mediated breast cancer cell migration, invasion and metastasis in vitro and in vivo. [Nat Commun] Abstract

G-Protein-Coupled Receptor GPR161 Is Overexpressed in Breast Cancer and Is a Promoter of Cell Proliferation and Invasion
Knockdown of GPR161 impairs proliferation of human basal breast cancer cell lines. Overexpression of GPR161 in human mammary epithelial cells increases cell proliferation, migration, intracellular accumulation of E-cadherin, and formation of multiacinar structures in 3D culture. [Proc Natl Acad Sci USA] Abstract

Nuclear Location of Tumor Suppressor Protein Maspin Inhibits Proliferation of Breast Cancer Cells without Affecting Proliferation of Normal Epithelial Cells
Researchers found a strong correlation between nuclear maspin and loss of Ki-67 protein in breast cancer cell lines, while there was no effect in normal epithelial cells from breast. [BMC Cancer] Full Article

Phospho-Aspirin (MDC-22) Inhibits Breast Cancer in Preclinical Animal Models: An Effect Mediated by EGFR Inhibition, p53 Acetylation and Oxidative Stress
Scientists synthesized phospho-aspirin (PA-2; MDC-22), a novel derivative of aspirin, and evaluated its chemotherapeutic and chemopreventive efficacy in preclinical models of triple negative breast cancer. [BMC Cancer] Full Article

High Glucose Level Promotes Migration Behavior of Breast Cancer Cells through Zinc and Its Transporters
Researchers investigated the breast cancer cell line, MCF-7 motility, which linked to invasion and metastasis, in high glucose level corresponding to hyperglycemia and the role of Zn and its transporter. [PLoS One]
Full Article

Thymoquinone, A Bioactive Component of Black Caraway Seeds, Causes G1 Phase Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells with Mutant p53
Scientists explored the growth inhibitory effect of thymoquinone (TQ) on two triple-negative breast cancer (TNBC) cell lines with mutant p53. Cell metabolism assays showed that TQ inhibited TNBC cell growth without affecting normal cell growth. [Nutr Cancer] Abstract

Genistein Induces Apoptosis and Autophagy in Human Breast MCF-7 Cells by Modulating the Expression of Proapoptotic Factors and Oxidative Stress Enzymes
Researchers demonstrated that genistein for 72 hours of treatment selectively reduced MCF-7 cell proliferation independent of estrogen receptor activation, while no cytotoxicity was observed in fibroblast cells. [Mol Cell Biochem] Abstract

The Hippo Transducer TAZ Interacts with the SWI/SNF Complex to Regulate Breast Epithelial Lineage Commitment
Researchers identified the Hippo transducer WWTR1/TAZ in a screen of transcription factors that are able to prompt lineage switching of mammary epithelial cells. Forced expression of TAZ in luminal cells induces them to adopt basal characteristics, and depletion of TAZ in basal and/or myoepithelial cells leads to luminal differentiation. [Cell Rep] Full Article | Press Release | Graphical Abstract


Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer
The combination of letrozole-lapatinib in early breast cancer was feasible, with expected and manageable toxicities. In unselected estrogen receptor-positive/human epidermal growth factor receptor 2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a similar overall clinical response rate and similar effect on Ki-67 and pAKT. [J Clin Oncol] Abstract

Clinical Significance of p95HER2 Overexpression, PTEN Loss and PI3K Expression in p185HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies
Scientists investigated the response to trastuzumab in terms of the potential roles of several oncogenic pathways and a truncated receptor protein, p95HER2, retrospectively. [Br J Cancer] Abstract

Read White Paper: Increase Success Rate Of Compounds In Toxicity Testing
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different
In this review, the authors summarize the current literature regarding the genomic and phenotypic similarities between BRCA 1/2-mutation related cancers, sporadic triple negative breast cancers, and sporadic ovarian cancers. [Front Oncol] Abstract

The Therapeutic Role of Fulvestrant in the Management of Patients with Hormone Receptor-Positive Breast Cancer
In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed. [Breast] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer
TapImmune Inc. reported that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. [TapImmune Inc.] Press Release

Insight Genetics and Vanderbilt-Ingram Cancer Center Partner to Improve Breast Cancer Diagnosis and Treatment
Insight Genetics, Inc. is collaborating with Vanderbilt-Ingram Cancer Center to enhance how researchers and oncologists classify and treat patients diagnosed with triple-negative breast cancer. [Insight Genetics, Inc.] Press Release

Astex Earns Milestone Payment on Initiation of Phase III Study
Astex Pharmaceuticals announced that it has received a milestone payment triggered by the commencement, by Novartis, of a Phase III study of LEE011. LEE011, in combination with other agents, has shown promising activity in pre-clinical studies in melanoma and breast cancer. [Astex Pharmaceuticals] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 4th International Breast Cancer Prevention Symposium
October 16-18, 2014
West Lafayette, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

NEW Postdoctoral Positions – Breast Cancer (Karolinska Institutet)

NEW Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Higher Scientific Officer – Breast Development (Institute of Cancer Research)

Postdoctoral Fellow – Process of Mammary Differentiation (University of British Columbia)

Studentship – Microtubules and End-Binding Proteins in Epithelial Remodeling and Breast Cancer Invasion (University of East Anglia)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Hodgkin Lymphoma and Breast Cancer (Hackensack University Medical Center)

Postdoctoral Position – Functions of Epigenetic Enzymes in Breast Cancer (University of Wisconsin-Madison)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us